Score Overview
PeriodNet IncomeRevenueScoreGrowthTrendConsistencyGrowthTrendConsistency
1 Year
—
—
—
—
—
—
—
1 Year
Score—
Net Growth—
Net Trend—
Net Income Consistency—
Rev Growth—
Rev Trend—
Revenue Consistency—
5 Years
—
—
50%
—
—
75%
—
5 Years
Score—
Net Growth—
Net Trend50%
Net Income Consistency—
Rev Growth—
Rev Trend75%
Revenue Consistency—
Explore the 2021 public Archive ranking →
Where Teva Pharma Industries Ltd ADR has ranked, year by year
Measure
Showing all available years ranking history by HDB Score.
Reached the top 50 on HDB Score in 1 year, the longest run being 1 in a row — but not in 2021.
- TEVA
1996: 11.5% · 2021: 46.6% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-28 | $ 38.88 | — |
1 Year2025-09-26 | $ 18.34 | 112.00% |
5 Years2021-09-28 | $ 9.60 | 305.00% |
10 Years2016-09-28 | $ 46.66 | -16.68% |
20 Years2006-09-28 | $ 26.55 | 46.42% |
30 Years1996-09-27 | $ 3.57 | 10x |
All Time1990-03-26 | $ 0.40 | 96x |
| Period | Last Price2026-09-28 | 1 Year2025-09-26 | 5 Years2021-09-28 | 10 Years2016-09-28 | 20 Years2006-09-28 | 30 Years1996-09-27 | All Time1990-03-26 |
|---|---|---|---|---|---|---|---|
| Price | $ 38.88 | $ 18.34 | $ 9.60 | $ 46.66 | $ 26.55 | $ 3.57 | $ 0.40 |
| Return | — | 112.00% | 305.00% | -16.68% | 46.42% | 10x | 96x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | |||
| 2025 | $ 17.25B | $ 1.41B | $ 3.55B |
| 2024 | $ 16.54B | -$ 1.63B | $ 3.30B |
| 2023 | $ 15.84B | -$ 559M | $ 3.22B |
| 2022 | $ 14.92B | -$ 2.44B | $ 2.80B |
| 2021 | $ 15.87B | $ 417M | $ 2.16B |
| 2020 | $ 16.65B | -$ 3.99B | $ 2.17B |
| 2019 | $ 16.88B | -$ 999M | $ 1.97B |
| 2018 | $ 18.85B | -$ 2.15B | $ 1.78B |
| 2017 | $ 22.38B | -$ 16.26B | $ 963M |
| 2016 | $ 21.90B | $ 329M | $ 988M |
| 2015 | $ 19.65B | $ 1.58B | $ 6.94B |
| 2014 | $ 20.27B | $ 3.05B | $ 2.22B |
| 2013 | $ 20.31B | $ 1.26B | $ 1.03B |
| 2012 | $ 20.31B | $ 1.96B | $ 2.87B |
| 2011 | $ 18.31B | $ 2.75B | $ 1.09B |
| 2010 | $ 16.12B | $ 3.33B | $ 1.28B |
| 2009 | $ 13.89B | $ 2.00B | $ 2.24B |
| 2008 | $ 11.08B | $ 635M | $ 1.90B |
| 2007 | $ 9.40B | $ 1.95B | $ 2.87B |
| 2006 | $ 8.40B | $ 546M | $ 2.04B |
| 2005 | $ 5.25B | $ 1.07B | $ 2.21B |
| 2004 | $ 4.79B | $ 331M | $ 1.04B |
| 2003 | $ 3.27B | $ 691M | $ 1.37B |
| 2002 | $ 2.51B | $ 410M | $ 1.04B |
| 2001 | $ 2.07B | $ 278M | $ 790M |
| 2000 | $ 1.74B | $ 148M | $ 424M |
| 1999 | $ 1.28B | $ 117M | $ 94M |
| 1998 | $ 1.11B | $ 68M | $ 49M |
| 1997 | $ 1.11B | $ 101M | $ 58M |
| 1996 | $ 953M | $ 73M | $ 69M |
| 1995 | $ 667M | $ 79M | $ 73M |
| 1994 | $ 587M | $ 71M | $ 50M |
| 1993 | $ 502M | $ 57M | $ 39M |
| 1992 | $ 406M | $ 32M | $ 13M |
| 1991 | $ 327M | $ 23M | $ 7M |
| IPO1990 | $ 329M | $ 20M | $ 15M |
Teva Pharma Industries Ltd ADR fundamental performance
Across Teva Pharma Industries Ltd ADR's full reported history, from 1990 to 2025, revenue grew from $ 329M to $ 17.25B and net income grew from $ 20M to $ 1.41B. Revenue increased in 71% of the years measured; net income in 60%.
Membership
Continue TEVA’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,816 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
